A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes

Y. Zhang; V. Stroobant; V. Russo; T. Boon; Pierre Van der Bruggen

doi:10.1034/j.1399-0039.2002.600503.x

A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes

Y. Zhang, V. Stroobant, V. Russo, T. Boon, Pierre Van der Bruggen

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

'Cancer-germline' genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of cancer patients. MAGE-A4 is expressed in more than 50% of carcinomas of esophagus, head and neck, lung, and bladder. We report here the identification of a new MAGE-A4 encoded peptide, which is recognized by a cytolytic T lymphocyte (CTL) clone on HLA-B*3701. The sequence of the peptide is SESLKMIF. It corresponds to the MAGE-A4_156-163 protein sequence. When tumor cells expressing MAGE-A4 were transfected with HLA-B*3701, they were recognized by the CTL clone, demonstrating that the peptide ought to be processed in tumor cells and could therefore serve as a target for therapeutic antitumoral vaccination.

Original language	English
Pages (from-to)	365-371
Number of pages	7
Journal	Tissue Antigens
Volume	60
Issue number	5
DOIs	https://doi.org/10.1034/j.1399-0039.2002.600503.x
Publication status	Published - Nov 1 2002

Keywords

Antigenic peptide
CTL
HLA-B37
MAGE-A4
Tumor

ASJC Scopus subject areas

Cell Biology
Immunology

Access to Document

10.1034/j.1399-0039.2002.600503.x

Cite this

@article{6824eafb3c024a878f6d248761970470,

title = "A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes",

abstract = "'Cancer-germline' genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of cancer patients. MAGE-A4 is expressed in more than 50% of carcinomas of esophagus, head and neck, lung, and bladder. We report here the identification of a new MAGE-A4 encoded peptide, which is recognized by a cytolytic T lymphocyte (CTL) clone on HLA-B*3701. The sequence of the peptide is SESLKMIF. It corresponds to the MAGE-A4156-163 protein sequence. When tumor cells expressing MAGE-A4 were transfected with HLA-B*3701, they were recognized by the CTL clone, demonstrating that the peptide ought to be processed in tumor cells and could therefore serve as a target for therapeutic antitumoral vaccination.",

keywords = "Antigenic peptide, CTL, HLA-B37, MAGE-A4, Tumor",

author = "Y. Zhang and V. Stroobant and V. Russo and T. Boon and {Van der Bruggen}, Pierre",

year = "2002",

month = nov,

day = "1",

doi = "10.1034/j.1399-0039.2002.600503.x",

language = "English",

volume = "60",

pages = "365--371",

journal = "Tissue Antigens",

issn = "0001-2815",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes

AU - Zhang, Y.

AU - Stroobant, V.

AU - Russo, V.

AU - Boon, T.

AU - Van der Bruggen, Pierre

PY - 2002/11/1

Y1 - 2002/11/1

N2 - 'Cancer-germline' genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of cancer patients. MAGE-A4 is expressed in more than 50% of carcinomas of esophagus, head and neck, lung, and bladder. We report here the identification of a new MAGE-A4 encoded peptide, which is recognized by a cytolytic T lymphocyte (CTL) clone on HLA-B*3701. The sequence of the peptide is SESLKMIF. It corresponds to the MAGE-A4156-163 protein sequence. When tumor cells expressing MAGE-A4 were transfected with HLA-B*3701, they were recognized by the CTL clone, demonstrating that the peptide ought to be processed in tumor cells and could therefore serve as a target for therapeutic antitumoral vaccination.

AB - 'Cancer-germline' genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of cancer patients. MAGE-A4 is expressed in more than 50% of carcinomas of esophagus, head and neck, lung, and bladder. We report here the identification of a new MAGE-A4 encoded peptide, which is recognized by a cytolytic T lymphocyte (CTL) clone on HLA-B*3701. The sequence of the peptide is SESLKMIF. It corresponds to the MAGE-A4156-163 protein sequence. When tumor cells expressing MAGE-A4 were transfected with HLA-B*3701, they were recognized by the CTL clone, demonstrating that the peptide ought to be processed in tumor cells and could therefore serve as a target for therapeutic antitumoral vaccination.

KW - Antigenic peptide

KW - CTL

KW - HLA-B37

KW - MAGE-A4

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0036866064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036866064&partnerID=8YFLogxK

U2 - 10.1034/j.1399-0039.2002.600503.x

DO - 10.1034/j.1399-0039.2002.600503.x

M3 - Article

C2 - 12492812

AN - SCOPUS:0036866064

VL - 60

SP - 365

EP - 371

JO - Tissue Antigens

JF - Tissue Antigens

SN - 0001-2815

IS - 5

ER -

A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this